Advertisement

Hormon- und Chemotherapie

  • Kurt W. Brunner
Part of the Handbuch der Medizinischen Radiologie / Encyclopedia of Medical Radiology book series (HDBRADIOL, volume 19 / 2)

Zusammenfassung

Das Mammakarzinom ist ein Malignom, das fast ausschließlich durch Fernmetastasierung und nicht durch lokales Tumorwachstum zum Tode führt. Rund 60% aller Patientinnen mit Mammakarzinom entwickeln innerhalb von zehn Jahren nach der primären Therapie Metastasen (Seidman, 1969). Langfristig können nur etwa 25% aller Patientinnen mit Mammakarzinom definitiv geheilt werden (Welbourn U. Burn, 1972). Das Risiko, nach erfolgreicher Radikaloperation eines Mammakarzinoms infolge Fernmetastasierung zu sterben, besteht auch noch nach einer Beobachtungsdauer von mehr als 20 Jahren (Ederer etal, 1963; Whitney et al, 1964). Rund 75% aller Patientinnen mit diesem Karzinom benötigen daher zu irgendeinem Zeitpunkt eine palliative Behandlung in einem nicht heilbaren Stadium. Der klinische Verlauf des Mammakarzinoms ist sehr unterschiedlich. Einige Karzinome führen rasch zum Tode, unabhängig davon, welche kurativen oder palliativen Therapien eingeleitet werden. Andere zeigen sehr langsame Verläufe. Dazwischen liegen zahlreiche Krankheitsverläufe, die heute in zunehmendem Maße auch im metastasierenden Stadium objektiv und subjektiv günstig beeinflußt werden können. Die großen Unterschiede im Spontanverlauf des Mammakarzinoms machen es schwierig, ohne exakt definierte Kriterien die Wirksamkeit irgendeiner Behandlungsmethode zu bewerten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahman, D.L., Eagan, R.T., Bisel, H.F., Hahn, R.G., O’Connell, M.J., Edmondson, J.H.: Evaluation of combination therapy with adriamycin (NSC-123 127) and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 6/3, 335–338 (1975a)Google Scholar
  2. Ahman, D.L., Bisel, H.F., Hahn, R.G. et al.: An analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-Fluorouracil, cyclophosphamide, and prednisone with or without vincristine. Cancer 36, 1925–1935 (1975b)CrossRefGoogle Scholar
  3. Ahman, D.L., O’Connell, M.J., Hahn, R.G. Bisel, H.F., Lee, R.A., Edmondson, J.H.: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N. Engl. J. Med. 29, 356–360 (1977)CrossRefGoogle Scholar
  4. Band, P.R., Tormey, D.C., Bauer, M.: Induction chemotherapy and maintenance chemo-hormontherapy in metastatic breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 18, 228 (1977)Google Scholar
  5. Baulieu, E.E.: Steroid receptors and hormone receptivity: new approaches in pharmacology and therapeutics. In: Breast cancer, trends in research and treatment. Heuson, J.C., Mattheiem, W.H., Rozencweig, M. (eds.), pp. 165–183. New York: Raven Press 1977Google Scholar
  6. Benjamin, R.S., Wiernik, P.H., Bachur, N.R.: Adriamycinefficacy, safety, and pharmacologic basis of a single dose schedule (abstr.). Cancer Chemother. Rep. 57, 98 (1973)Google Scholar
  7. Blumenschein, G., Cardenas, J., Freireich, E., Gottlieb, J.: FAC chemotherapy for breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 15, 193 (1974)Google Scholar
  8. Bogden, A.E., Ebber, H.J., Taylor, D.J., Gray, J.H.: Comparative study of surgery, chemotherapy and immunotherapy alone and in combination on metastases of 13762 mammary adenocarcinoma. Cancer Res. 34, 1627–1631 (1974)PubMedGoogle Scholar
  9. Bonadonna, G., Monfardini, S., DeLena, M., Fossati-Bellani, F., Beretta, G.: Clinical trials with adriamycin. Results of a three-year study. In: International symposium on adriamycin. Carter, S.K., Di-Marco, A., Ghione, M., Krakoff, I.H., Mathé, G. (eds.), pp. 139–152. Berlin, Heidelberg, New York: Springer 1972CrossRefGoogle Scholar
  10. Bonadonna G., Rossi, A., Valagussa, P., Banfi, A., Veronesi, U.: The C.M.F program for operable breast cancer with positive axillary nodes. Cancer 39, 2904–2915 (1977)PubMedCrossRefGoogle Scholar
  11. Broder, L.E., Tormey, D.C.: Combination chemotherapy of carcinom of the breast. Cancer Treat. Rev. 1, 183–203 (1974)CrossRefGoogle Scholar
  12. Brunner, K.W., Nagel, G.A.: Internistische Krebstherapie. Berlin, Heidelberg, New York: Springer 1976Google Scholar
  13. Brunner, K.W., Sonntag, R.W., Martz, G., Senn, H.J., Obrecht, P., Alberto, P.: A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36, 1208–1219 (1975)PubMedCrossRefGoogle Scholar
  14. Brunner, K.W., Sonntag, R.W., Alberto, P., Senn, H.J., Martz, G., Obrecht, P.: Combined chemo-and hormonal therapy in advanced breast cancer. Cancer 39, 2923–2933 (1977)PubMedCrossRefGoogle Scholar
  15. Canellos, G.P., Taylor, S.G., Band, P., Pocock, S.: Combination chemotherapy for advanced breast cancer (abstr.). Proc. XIth Int. Cancer Congr. 3, 596 (1974)Google Scholar
  16. Canellos, P.G., Pocock S.J., Taylor, S.G. et al.: Combination chemotherapy for metastatic breast carcinoma. Cancer 38, 1882–1886 (1976)PubMedCrossRefGoogle Scholar
  17. Carbone, P.P., Bauer, M., Band, P., Tormey, D.: Chemotherapy of disseminated breast cancer. Cancer 39, 2916–2922 (1977)PubMedCrossRefGoogle Scholar
  18. Carter, S.K.: Chemotherapy of breast cancer: current status. In: Breast cancer, trends in research and treatment. Heuson, J.C., Mattheiem, W.H., Rozencweig, M. (eds.), pp. 196–215. New York: Raven Press 1976Google Scholar
  19. Cole, M.P.: Suppression of ovarian function in primary breast cancer. In: Prognostic factors in breast cancer. Forrest, A.P.M., Kunkler P.B. (eds.), p. 146. Edinburgh, London: Livingstone 1968Google Scholar
  20. Cooper, R.: Combination chemotherapy in hormone resistant breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 10, 15 (1969)Google Scholar
  21. Cortes, E.P., Holland, J.F., Wang, J.J., Sinks, L.F., Blom, J., Senn, H.J., Bank, A., Glidewell, O.: Amputation and adriamycin in primary osteosarcoma. N. Engl. J. Med. 291, 998–1002 (1974)PubMedCrossRefGoogle Scholar
  22. Creech, R., Harris, D., Grotzinger, P., Engstrom, P.: Low dose therapy of metastatic breast cancer with CAMF vs. sequential C.M.F and adriamycin (abstr.). Proc. Am. Soc. Clin. Oncology 18, 300 (1977)Google Scholar
  23. Davis, H.L., Ramirez, G., Ellerby, R.A., Ansfield, F.J.: Five-drug therapy in advanced breast cancer. Factors influencing toxicity and response. Cancer 34, 239–245 (1974)PubMedCrossRefGoogle Scholar
  24. DeJager, R., Kaufman, R., Ocahoa, M., Krakoff, L.H.: Chemotherapy of advanced breast cancer with a combination of Cytoxan, adriamycin, and 5-FU (CAF) (abstr.). Proc. Am. Assoc. Cancer Res. 16, 273 (1975)Google Scholar
  25. DeLena, M., DePalo, G.M., Bonadonna, G., Beretta, G., Bajetta, E.: Terapia del carcinoma mammario metastatizzato con ciclofosfamide, methotrexate, vincristina e fluorouracile. Tumori 59, 11–24 (1973)Google Scholar
  26. DeLena, M., Brambilla, C., Morabito, A., Bonadonna, G.: Adriamycin plus vincristine compared with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer. Cancer 35, 1108–1115 (1975)CrossRefGoogle Scholar
  27. Eagan, R.T., Ahman, D.L., Admondson, J.H., Hahn, G., Bisel, H.F.: Controlled evaluation of the combination of adriamycin (NSC-123 127), vincristine (NSC-67 574) and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 6/3, 339–342 (1975)Google Scholar
  28. Ederer, R., Cutler, S.J., Goldenberg, I.S., Eisenberg, H.: Causes of death among long-term survivors from breast cancer in Connecticut. J. Natl. Cancer Inst. 30, 933–947 (1963)Google Scholar
  29. Fernbach, D.J., Martyn, D.T.: Role of dactinomycyn in the improved survival of children with Wilms’ tumor. J. Am. Med. Assoc. 195, 1005–1009 (1966)CrossRefGoogle Scholar
  30. Fisher, B., Ravdin, R.G., Ausman, R.K., Slack, N.H. et al.: Surgical adjuvant chemotherapy in cancer of the breast. Results in a decade of cooperative investigation. Ann. Surg. 168, 337–356 (1968)PubMedCrossRefGoogle Scholar
  31. Fisher, B., Slack, N, Bross, I.D.J., et al.: Cancer of the breast: size of neoplasm and prognosis. Cancer 24, 1071–1080 (1969)PubMedCrossRefGoogle Scholar
  32. Fisher, B., Slack, N., Katrych, D., Wolmark, N.: Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg. Gynecol. Obstet. 140, 528–534 (1975)PubMedGoogle Scholar
  33. Fisher, B. et al.: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. Cancer 39, 2883–2901 (1977)PubMedCrossRefGoogle Scholar
  34. Forrest, A.P.M., Kunkler, P.B. (eds.): Prognostic factors in breast cancer. Edinburgh, London: Livingstone 1968Google Scholar
  35. Fracchia, A.A., Farrow, J.H., Miller, T.R., Rollefsen, R.H., Greenberg, E.J., Knapper, W.H.: Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surg. Gynecol. Obstet. 133, 241–246 (1971)PubMedGoogle Scholar
  36. Greenspan, E.: Response of advanced breast cancer to the combination of the antimetabolite, methotrexate, and the alkylating agent thio-tepa. Mt. Sinai J. Med. N.Y. 30, 246–267 (1963)Google Scholar
  37. Greenspan, E.: Combination cytotoxic chemotherapy in advanced disseminated breast cancer. Mt. Sinai J. Med. N.Y. 33, 1–27 (1966)Google Scholar
  38. Grinberg, R., Nemoto, T., Dao, T.L.: Vincristine: dosage and response in breast cancer. Cancer Chemother. Rep. 45, 57–61 (1965)PubMedGoogle Scholar
  39. Groupe Européen du Cancer du Sein: Le traitement hormonal du cancer du sein en phase avancée: Comparaison entre le propionate de testosterone et la combinaison propionate de testosterone — delta-1 testololactone. Rev. Fr. Etud. Clin. Biol. 9, 88–90 (1964)Google Scholar
  40. Hanham, I.W.F., Newton, K.A., Westbury, G.: Seventy-five cases of solid tumors treated by a modified quadruple chemotherapy regime. Br. J. Cancer 25, 462–478 (1971)PubMedCrossRefGoogle Scholar
  41. Harvey, H.A., White, D.S., Lipton, A.: Five drug regimen plus adriamycin in metastatic breast cancer (abstr.). Proc. Am. Soc. Clin. Oncology 16, 255 (1975)Google Scholar
  42. Holland, J., Sharlav, C., Galiani, S. et al.: Vincristine treatment of advanced cancer: a comparative study of 392 cases. Cancer Res. 33, 1258–1264 (1973)PubMedGoogle Scholar
  43. Hoogstraten, B.: Adriamycin (NSC-123 127) in the treatment of advanced breast cancer: studies by the Southwest Oncology Group. Cancer Chemother. Rep. 6/3, 329–334 (1975)Google Scholar
  44. Hoogstraten, B., George, S.L., Samal, B. etal.: Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38, 13–20 (1976)PubMedCrossRefGoogle Scholar
  45. Horton, J., Dao, T., Cunningham, T., Nemoto, T. et al.: Alternating combination therapy for metastatic breast cancer (abstr.). Proc. Am. Soc. Clin. Oncology. 17, 247 (1976)Google Scholar
  46. Jaffe, N. et al.: Adjuvant methotrexate and citrovorumfactor for treatment of osteogenic sarcoma. N. Engl. J. Med. 291, 944–948 (1974)CrossRefGoogle Scholar
  47. James, D.H.: Combination chemotherapy of childhood neuroblastoma. J. Am. Med. Assoc. 194, 123–128 (1965)CrossRefGoogle Scholar
  48. Kennedy, B.J., Mielke, P.W. Jr, Fortuny, I.E.: Therapeutic castration versus prophylactic castration in breast cancer. Surg. Gynecol. Obstet. 118, 524–529 (1964)PubMedGoogle Scholar
  49. Leclercq, G., Heuson, J.C., Deboel, M.C., Mattheiem, W.H.: Oestrogen receptors in breast cancer. A changing concept. Br. Med. J. 1975 1, 185–189PubMedCrossRefGoogle Scholar
  50. Leone, L.S., Rege, V.: Treatment of metastatic, recurrent or inoperable carcinoma of breast with VCR/ Pred/5-FU/Mtx/Cyclo (Reg I) vs. VCR/Pred/5-FU (Reg II) (abstr.). Proc. Am. Assoc. Cancer Res. 14, 125 (1973)Google Scholar
  51. Lloyd, R., Jones, S.E., Salmon, S.E., and Southwest Oncology Group Members: Phase II trial of adriamycin and cyclohphosphamide: a Southwest Oncology Group Pilot Study. Proc. Am. Assoc. Cancer Res. 16, 265 (1975)Google Scholar
  52. Lokich, J.J., Skarin, A.T.: Five drug combination chemotherapy for disseminated adenocarcinoma. Cancer Chemother. Rep. 56, 761–787 (1972)PubMedGoogle Scholar
  53. McGuire, W.L., Carbone, P.P., Vollmer, E.P. (eds.): Estrogen receptors in human breast cancer. New York: Raven Press 1975Google Scholar
  54. McGuire, W.L., Horwitz, K.B, Pearson, O.H., Segaloff, A.: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39, 2934–2974 (1977)PubMedCrossRefGoogle Scholar
  55. Middleman, E., Luce, J.K., Frei, E.: Clinical trials with adriamycin. Cancer 28, 844–50 (1971)PubMedCrossRefGoogle Scholar
  56. Muss, H.B., White, D.R., Cooper, M.R., Richards, F.C., Spurr, C.L.: A randomyzed study of two five-drug regimens in advanced breast cancer (abstr.). Proc. Am. Soc. Clin. Oncology 18, 272 (1977)Google Scholar
  57. Nemoto, T., Horton, J., Cunningham, T. etal.: Up date report: comparison of combination chemotherapy (FCP) vs. adriamycin (ADM) vs. adrenalectomy (ADX) in breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 16, 46 (1975)Google Scholar
  58. Philips, R.F., Higinbotham, N.Z.: The curability of Ewing’s endothelioma of bone in children. J. Pediatr. 70, 391–398 (1967)CrossRefGoogle Scholar
  59. Rozencweig, M., Heuson, J.-A.: Breast cancer: prognostic factors and clinical evaluation. In: Cancer therapy: prognostic factors and criteria of response. Staquet, M.J. (ed.), pp. 139–183. New York: Raven Press 1975Google Scholar
  60. Salmon, S., Jones, S.: Chemotherapy of advanced breast cancer with a combination of adriamycin and cyclophosphamide (abstr.). Proc. Am. Assoc. Cancer Res. 15, 90 (1974)Google Scholar
  61. Schabel, F.M.: Concepts for systemic treatment of micrometastases. Cancer 35, 15–24 (1975)PubMedCrossRefGoogle Scholar
  62. Schabel, M.F.: Rationale for adjuvant chemotherapy. Cancer [Suppl.] 39, 2846–2867 (1977)Google Scholar
  63. Seidman, H.: Cancer of the breast: statistical and epidemiological data. Cancer 24, 1355–1378 (1969)PubMedCrossRefGoogle Scholar
  64. Smalley, R., Bornstein, R.: C-A-F treatment of metastatic breast carcinoma (abstr.). Proc. Am. Assoc. Cancer Res. 16, 265 (1975)Google Scholar
  65. Smalley, R.V., Murphy, S., Chan, Y.K., Huguely, C.M.: Comparison of two five-drug regimens vs. sequential chemotherapy in metastatic breast carcinoma (abstr.). Cancer Chemother. Rep. 57, 110 (1973)Google Scholar
  66. Stolfi, R.L., Martin, D.S., Fugmann, R.A.: Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy. Cancer Chemother. Rep. 55, 239–249 (1971)PubMedGoogle Scholar
  67. Stoll, B.A. (ed.): Mammary cancer and neuroendocrine therapy. London: Butterworths 1974Google Scholar
  68. Stutz, F.H., Blom, J., Tormey, D.C.: Combination chemotherapy in disseminated carcinoma of the breast. Oncology 29, 139–146 (1974)PubMedCrossRefGoogle Scholar
  69. Sutow, W.W.: Chemotherapy in childhood cancer (except leukemia). An appraisal. Cancer 18, 1585–1595 (1965)Google Scholar
  70. Sutow, W., Sullivan, P., Fernbach, D.: Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Proc. Am. Assoc. Cancer Res. 15, 20 (1974)Google Scholar
  71. Tormey, D.C.: Adriamycin (NSC-123 127) in breast cancer: an overview of studies. Cancer Chemotherap. Rep. 6/3, 319–327 (1975a)Google Scholar
  72. Tormey, D.C.: Combined chemotherapy and surgery in breast cancer: a review. Cancer 36, 881–892 (1975b)CrossRefGoogle Scholar
  73. Tormey, D.C., Simon, R.M., Lippman, M.E., Bull, J.M., Myers, C.E.: Evaluation of tamoxifen dose in advanced breast cancer. Cancer Treat. Rep. 60, 1451–1459 (1976)PubMedGoogle Scholar
  74. Tormey, D., Carbone, P., Band, P.: Breast cancer survival in single and combination chemotherapy trials since 1968. Proc. Am. Assoc. Cancer Res. 18, 64 (1977)Google Scholar
  75. Welbourn, M.A., Burn, I.J.: Current concepts — treatment of advanced mammary cancer. N. Engl. J. Med. 287, 398–400 (1972)PubMedCrossRefGoogle Scholar
  76. Whitney, D.J., Smith, D.G., Szilagyi, D.E.: Meaning of five-year cure in cancer of the breast. Arch. Surg. 88, 637–644 (1964)PubMedCrossRefGoogle Scholar
  77. Young, R.C., Lippman, M.E., DeVita, T.V., Bull, J., Tormey, D.C.: Perspectives in the treatment of breast cancer: 1976. Ann. Intern. Med. 86, 784–798 (1976)Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1982

Authors and Affiliations

  • Kurt W. Brunner

There are no affiliations available

Personalised recommendations